Engineered antibody for reducing localized fibrotic scarring

用于减少局部纤维化疤痕的工程化抗体

基本信息

  • 批准号:
    8102585
  • 负责人:
  • 金额:
    $ 20.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-04-01 至 2013-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The main goal of the proposed study is to engineer inhibitors of excessive scarring. The specific target for these inhibitors is formation of collagen fibrils, structures that constitute the main mass of fibrotic deposits. The principle for such an approach to limit pathological accumulation of fibrotic deposits has already been tested in vitro and in vivo, and its high therapeutic potential has been demonstrated. Since antibodies can block specific interactions through high-affinity binding to interacting sites, we focus on developing antibody-based blockers of the critical collagen/collagen interaction. Specifically, we will engineer and test human-relevant variants of a prototypic mouse-derived antibody that in our initial studies demonstrated a high potential to limit fibril formation. The need for such human-relevant antibody-based blockers of excessive scarring is driven by our long-term plans to apply proposed therapeutic approach in humans. The hypothesis driving the current proposal is that gene-engineered variants of a monoclonal antibody that blocks collagen fibril formation will have similar inhibitory potential as that of their prototypic counterpart. Based on the broad analogy to a number of clinically effective antibody-based therapeutics, we propose that the variants that we plan to develop here will be active and suitable for preclinical and clinical tests. Moreover, in the future, the basic design of the planned antibody variants will serve as a catalyst to develop their fully humanized versions through complementarily determining regions (CDR) grafting. Two specific aims are proposed to test the above hypothesis: (1) To genetically engineer antibody-based inhibitors of excessive scarring. (2) To test potential of genetically engineered inhibitors of excessive scarring. We expect that the overall impact of the results of our proposed research on the prevention of excessive scarring will be high. This notion is based on the fact that excessive deposition of collagen fibrils is a common characteristic of all fibrotic scars. Thus, we predict that the antibody-based inhibitors we propose to develop here in a specific model could also serve as prototypes for the development of similar inhibitors of fibrotic scars in a wide range of connective tissues and organs. PUBLIC HEALTH RELEVANCE: Formation of fibrotic scars is a serious medical problem that affects all collagen-rich connective tissues. Because one of the hallmarks of fibrosis is excessive accumulation of collagen fibrils, the objective of the proposed study is to develop novel approaches to inhibit fibrosis by blocking the extracellular process of collagen fibril assembly. Since results of our study will deliver antibody-based inhibitors suitable for tests in humans, the relevance of our proposed research for public health is high.
描述(由申请方提供):拟定研究的主要目标是设计过度瘢痕形成的抑制剂。这些抑制剂的具体目标是形成胶原纤维,构成纤维化沉积物的主要质量的结构。这种方法限制纤维化沉积物的病理性积累的原理已经在体外和体内进行了测试,并且已经证明了其高治疗潜力。由于抗体可以通过与相互作用位点的高亲和力结合来阻断特异性相互作用,因此我们专注于开发关键胶原/胶原相互作用的基于抗体的阻断剂。具体来说,我们将设计和测试原型小鼠衍生抗体的人类相关变体,这些变体在我们的初步研究中表现出限制原纤维形成的高潜力。对这种过度瘢痕形成的人类相关的基于抗体的阻断剂的需求是由我们在人类中应用所提出的治疗方法的长期计划驱动的。驱动当前提议的假设是,阻断胶原原纤维形成的单克隆抗体的基因工程变体将具有与其原型对应物相似的抑制潜力。基于对许多临床有效的基于抗体的疗法的广泛类比,我们建议我们计划在这里开发的变体将是活性的,并且适合于临床前和临床测试。此外,在未来,计划的抗体变体的基本设计将作为催化剂,通过互补决定区(CDR)移植开发其完全人源化的版本。提出了两个具体的目标来测试上述假设:(1)基因工程抗体为基础的过度疤痕抑制剂。(2)为了测试基因工程抑制过度疤痕的潜力。 我们预计,我们提出的研究结果对预防过度疤痕的总体影响将是很高的。这一概念是基于这样一个事实:胶原纤维的过度沉积是所有纤维化疤痕的共同特征。因此,我们预测,我们提出在特定模型中开发的基于抗体的抑制剂也可以作为在广泛的结缔组织和器官中开发类似的纤维化瘢痕抑制剂的原型。 公共卫生相关性:纤维化瘢痕的形成是一个严重的医学问题,影响所有富含胶原蛋白的结缔组织。由于纤维化的标志之一是过度积累的胶原纤维,所提出的研究的目的是开发新的方法来抑制纤维化,通过阻断细胞外过程的胶原纤维组装。由于我们的研究结果将提供适用于人类测试的基于抗体的抑制剂,因此我们提出的研究对公共卫生的相关性很高。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDRZEJ FERTALA其他文献

ANDRZEJ FERTALA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDRZEJ FERTALA', 18)}}的其他基金

Novel therapy for arthrofibrosis
关节纤维化的新疗法
  • 批准号:
    10759562
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
Engineered antibody for reducing localized fibrotic scarring
用于减少局部纤维化疤痕的工程化抗体
  • 批准号:
    8265916
  • 财政年份:
    2011
  • 资助金额:
    $ 20.91万
  • 项目类别:
Molecular Genetics of the Cutaneous BMZ in EB
EB 皮肤 BMZ 的分子遗传学
  • 批准号:
    8013622
  • 财政年份:
    2008
  • 资助金额:
    $ 20.91万
  • 项目类别:
Molecular Genetics of the Cutaneous BMZ in EB
EB 皮肤 BMZ 的分子遗传学
  • 批准号:
    7567515
  • 财政年份:
    2008
  • 资助金额:
    $ 20.91万
  • 项目类别:
Molecular Genetics of the Cutaneous BMZ in EB
EB 皮肤 BMZ 的分子遗传学
  • 批准号:
    8213724
  • 财政年份:
    2008
  • 资助金额:
    $ 20.91万
  • 项目类别:
Molecular Genetics of the Cutaneous BMZ in EB
EB 皮肤 BMZ 的分子遗传学
  • 批准号:
    7759538
  • 财政年份:
    2008
  • 资助金额:
    $ 20.91万
  • 项目类别:
Molecular Genetics of the Cutaneous BMZ in EB
EB 皮肤 BMZ 的分子遗传学
  • 批准号:
    7379891
  • 财政年份:
    2008
  • 资助金额:
    $ 20.91万
  • 项目类别:
Site Specific Interactions and Collagen Self Assembly
位点特异性相互作用和胶原蛋白自组装
  • 批准号:
    6459210
  • 财政年份:
    2002
  • 资助金额:
    $ 20.91万
  • 项目类别:
Altered Matrix-Cells and Intermolecular Interactions
改变的基质细胞和分子间相互作用
  • 批准号:
    6663707
  • 财政年份:
    2002
  • 资助金额:
    $ 20.91万
  • 项目类别:
Site Specific Interactions and Collagen Self Assembly
位点特异性相互作用和胶原蛋白自组装
  • 批准号:
    8265911
  • 财政年份:
    2002
  • 资助金额:
    $ 20.91万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 20.91万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了